Shojiro Yamamoto
Overview
Explore the profile of Shojiro Yamamoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
344
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Naganuma M, Shiga H, Shimoda M, Matsuura M, Takenaka K, Fujii T, et al.
J Gastroenterol
. 2025 Jan;
PMID: 39883201
Background: Despite the availability of several biologics for ulcerative colitis (UC), there remains a critical need to identify first-line treatment biologics. The superiority of infliximab (IFX) over vedolizumab (VED) and...
2.
Fukuda T, Yamazaki H, Miyatani Y, Sawada T, Shibuya N, Fukuo Y, et al.
Aliment Pharmacol Ther
. 2024 Apr;
60(1):43-51.
PMID: 38651779
Background: Endoscopic healing (EH) is a therapeutic target in ulcerative colitis (UC). However, even patients who have achieved EH relapse frequently. Aims: To investigate the association between recent steroid use...
3.
Naganuma M, Nakamura N, Kunisaki R, Matsuoka K, Yamamoto S, Kawamoto A, et al.
J Gastroenterol
. 2024 Jan;
59(4):302-314.
PMID: 38277006
Background: Hospitalization for ulcerative colitis (UC) is potentially life-threatening. Severe disease in the Japanese criteria which modifies the Truelove-Witts' criteria might encompass more fulminant cases than the definition for acute...
4.
Horiguchi T, Sumiyoshi M, Nagatomo E, Sakamoto K, Ogawa S, Ichinari N, et al.
BMC Infect Dis
. 2023 Dec;
23(1):863.
PMID: 38062360
Background: Luteibacter jiangsuensis is a gram-negative aerobic bacillus that was first isolated from soil samples at a pesticide factory in China and reported in 2011. Here, we describe the first...
5.
Naganuma M, Kobayashi T, Kunisaki R, Matsuoka K, Yamamoto S, Kawamoto A, et al.
J Gastroenterol
. 2023 Oct;
58(12):1198-1210.
PMID: 37831183
Background: This multicenter observational cohort study aimed to evaluate the utilization and short-term efficacy of advanced therapy (AT) in hospitalized patients with acute severe ulcerative colitis (ASUC). Methods: In total,...
6.
Hasuike S, Nagata K, Sasaki H, Hirata T, Suzuki S, Komaki Y, et al.
Intern Med
. 2023 Apr;
62(21):3143-3149.
PMID: 37032077
We reported a notable case of inflammatory hepatocellular adenoma that grew during pregnancy, consequently changing its appearance on magnetic resonance imaging remarkably. A 5-months-pregnant 35-year-old woman presented with a 37-mm...
7.
Kita T, Ashizuka S, Takeda T, Matsumoto T, Ohmiya N, Nakase H, et al.
J Gastroenterol Hepatol
. 2022 Jul;
37(11):2051-2059.
PMID: 35840351
Background And Aim: Adrenomedullin is a bioactive peptide with many pleiotropic effects, including mucosal healing and immunomodulation. Adrenomedullin has shown beneficial effects in rodent models of inflammatory bowel disease and,...
8.
Komaki Y, Ozono Y, Nakamura K, Iwakiri H, Hasuike S, Sueta M, et al.
BMC Gastroenterol
. 2022 Apr;
22(1):210.
PMID: 35484503
Background: It is estimated that approximately 50% of patients with hepatitis C virus (HCV) infection in Japan are currently over 75 years old. However, patients aged ≥ 75 years are...
9.
Kita T, Ashizuka S, Ohmiya N, Yamamoto T, Kanai T, Motoya S, et al.
J Gastroenterol
. 2020 Nov;
56(2):147-157.
PMID: 33140199
Background: Adrenomedullin (AM) is a bioactive peptide having many pleiotropic effects, including mucosal healing and immunomodulation. AM has shown beneficial effects in rodent models and in preliminary study for patients...
10.
Suzuki S, Kawakami H, Miike T, Yamamoto S
Intern Med
. 2020 Oct;
60(6):957-958.
PMID: 33087677
No abstract available.